Neuraxpharm launch first products in UK

Sarepta & StrideBio to advance novel gene therapies for CNS & neuromuscular targets
Credit: Shutterstock.com/ Sebastian Kaulitzki

Neuraxpharm Group, a European pharmaceutical company focussed on central nervous system (CNS) disorders, has launched its first products in the UK.

The company will be launching differentiated and speciality generics in the UK where the CNS pharma market represents 11% of the total market in Europe.

“Establishing a strong presence in the UK will enable us to build on our position as a CNS specialist in Europe offering consumer healthcare products, standard generics and added value medicines,” said CEO Jörg-Thomas Dierks.

The company’s new UK division will be led by the newly appointed General manager Craig Bowen.

Before joining Neuraxpharm UK, he was Associate Director and Commercial Head for UK and Ireland in Par Laboratories where he led the creation and initial set up of the Par affiliate in the UK and implemented the commercial strategy to launch Par products into the UK, EU and other international markets.